

COMPLEMENT C3 ANTIBODIES AND OTHER COMPLEMENT RELATED ANTIBODIES

For over 65 years, Cedarlane has provided high-quality complement-related products to the life science community.


Cedarlane offers various formats of complement reagents, as well as an extensive range of recombinant proteins and antibodies.

Antibodies to complement components, regulators, and receptors are available in multiple formats, including purified, low endotoxin and conjugated to biotin, FITC, PE, APC, Alexa Dyes and horseradish peroxidase.



Understanding C3: Core Protein in Complement Pathways

Complement component C3 (C3) is a protein in the innate immune system that plays a central role in both the classical and alternative complement activation pathways. In both pathways, it is cleaved by C3 convertases, releasing the C3a anaphylatoxin and the C3b fragment, which binds to microbial surfaces and incorporates into C5 convertases. The cleavage of C5 into C5a and C5b by these C5 convertases is the convergence point of the complement pathways and ultimately leads to the formation of the membrane attack complex (MAC).




Opsonization of cells with ofatumumab (OFA) promotes more rapid blebbing and streamer formation than opsonization with rituximab (RTX). (A) Daudi cells were opsonized with Al488 OFA and then chilled on ice before reaction with normal human serum and Al647 mAb clone 3E7. The chilled mixture was then placed on the heated (37°C) microscope stage and analyzed by SDCM; merged 488 nm/647 nm images. (B) Same procedure as in A, but Al488 RTX was used instead of Al488 OFA. (Adapted from Beum PV, et al. (2008). *J Immunol.* 181(1):822-32.)

Streamers can be observed in bright field (phase imaging), and have the same appearance as streamers detected by fluorescence. Daudi cells were opsonized with ofatumumab, and then reacted with normal human serum and Al488 mAb clone 3E7. (A) 488 nm image. (B) bright field images of the same field as in A. (Adapted from Beum PV, et al. (2008). *J Immunol.* 181(1):822-32.)


C3 ANTIBODIES

SPECIFICITY	FORMAT	CLONE	ISOTYPE	SPECIES REACTIVITY	APPLICATIONS	SIZE	CAT #
C3	Purified	RmC11H9	Rat IgG2a	Mouse	IF, E, WB, F, C	250 µg	CL7503AP
	APC	RmC11H9	Rat IgG2a	Mouse	IF, E	100 µg	CL7503APC
	Biotin	RmC11H9	Rat IgG2a	Mouse	IF, E, WB, F, C	100 µg	CL7503B
	FITC	RmC11H9	Rat IgG2a	Mouse	IF, F	100 µg	CL7503F
	PE	RmC11H9	Rat IgG2a	Mouse	F	50 µg	CL7503PE
C3a/C3a(desArg)/C3	Purified	K13/16	Mouse IgG1, k	Human	FN, IP, E, WB	200 µg	CL7623AP
	Biotin	K13/16	Mouse IgG1, k	Human	IP, E, WB	100 µg	CL7623B
	FITC	K13/16	Mouse IgG1, k	Human	WB	100 µg	CL7623F
	PE	K13/16	Mouse IgG1, k	Human	WB	50 µg	CL7623PE
C3/C3b/iC3b	Purified	6C9	Mouse IgG1	Human/Mouse	F, E	2250 µg	CL7631AP
	APC	6C9	Mouse IgG1	Human/Mouse	F	100 µg	CL7631APC
	Biotin	6C9	Mouse IgG1	Human/Mouse	F, E	100 µg	CL7631B
	FITC	6C9	Mouse IgG1	Human/Mouse	F	100 µg	CL7631F
	Purified	10C7	Mouse IgG1	Human/Mouse	F, E	250 µg	CL7632AP
	Biotin	10C7	Mouse IgG1	Human/Mouse	F, E	100 µg	CL7632B
	FITC	10C7	Mouse IgG1	Human/Mouse	F	100 µg	CL7632F
	PE	10C7	Mouse IgG1	Human/Mouse	F	50 µg	CL7632PE
	Purified	7C12	Mouse IgG1	Human	WB, F, E	250 µg	CL7636AP
	Biotin	7C12	Mouse IgG1	Human	WB, F, E	100 µg	CL7636B
	FITC	7C12	Mouse IgG1	Human	WB, F	100 µg	CL7636F
	PE	7C12	Mouse IgG1	Human	WB, F	50 µg	CL7636PE
	Purified	3E7	Mouse IgG1	Human	B-AP, F, E	250 µg	CL7651AP
	APC	3E7	Mouse IgG1	Human	F	100 µg	CL7651APC
	Biotin	3E7	Mouse IgG1	Human	F, E	100 µg	CL7651B
	FITC	3E7	Mouse IgG1	Human	F	100 µg	CL7651F
	PE	3E7	Mouse IgG1	Human	F	50 µg	CL7651PE
	Purified	5G9	Mouse IgG2a	Human	B-CP, F, E	250 µg	CL7652AP
	APC	5G9	Mouse IgG2a	Human	F	100 µg	CL7652APC
	FITC	5G9	Mouse IgG2a	Human	F	100 µg	CL7652F
C3/C3b/iC3b/C3dg	Purified	1H8	Mouse IgG2a	Human	WB, F, E	250 µg	CL7637AP
	APC	1H8	Mouse IgG2a	Human	WB, F	100 µg	CL7637APC
	Biotin	1H8	Mouse IgG2a	Human	WB, F, E	100 µg	CL7637B
	FITC	1H8	Mouse IgG2a	Human	WB, F	100 µg	CL7637F
	PE	1H8	Mouse IgG2a	Human	WB, F	50 µg	CL7637PE


Log Fluorescence Intensity



C3H/He mouse thymocytes incubated with anti-mouse CD90 (Thy 1.2) (clone: 5a-8) and fresh mouse serum were stained with anti-mouse C3, PE (CL7503PE) (filled histogram) or rat IgG2a, PE isotype control (CLCR2A04) (open histogram).



Balb/c mouse thymocytes incubated with rabbit anti-mouse T cells and fresh human serum were stained with anti-human C3/C3b/iC3b, PE (CL7636PE) (filled histogram) or mouse IgG1, PE isotype control (CLCMG104) (open histogram).



C3H/He mouse thymocytes incubated with rabbit anti-mouse T cells and fresh human serum were stained with anti-human C3/C3b/iC3b/C3dg, FITC (CL7637F) (filled histogram) or mouse IgG2a, FITC isotype control (CLCMG2A01) (open histogram).

COMPLEMENT RELATED ANTIBODIES

SPECIFICITY	FORMAT	CLONE	ISOTYPE	SPECIES REACTIVITY	APPLICATIONS	SIZE	CAT #
C1q	Purified	Polyclonal	Rabbit IgG	Human	F, WB, E	200 µg	CL7633AP
	Biotin	Polyclonal	Rabbit IgG	Human	F, WB, E	100 µg	CL7633B
	HRPO	Polyclonal	Rabbit IgG	Human	WB, E	100 µg	CL7633HP
	Purified	MhC5B9	Mouse IgG1	Human	IF, C, WB, E	250 µg	CL7611AP
	Biotin	MhC5B9	Mouse IgG1	Human	IF	100 µg	CL7611B
	FITC	MhC5B9	Mouse IgG1	Human	IF	100 µg	CL7611F
	PE	MhC5B9	Mouse IgG1	Human	IF	50 µg	CL7611PE
	Aff. Purified	Polyclonal	Goat IgG	Human	E	1 mg	CL7341AP
	Purified	RmC7H8	Rat IgG1	Mouse	IF, C, WB, E	250 µg	CL7501AP
	Biotin	RmC7H8	Rat IgG1	Mouse	IF, E, WB	100 µg	CL7501B
FITC	RmC7H8	Rat IgG1	Mouse	IF	100 µg	CL7501F	
PE	RmC7H8	Rat IgG1	Mouse	IF, E, WB, F	50 µg	CL7501PE	
C3a receptor	Purified	74	Mouse IgG1	Rat	F, C	250 µg	CL031AP
	Biotin	74	Mouse IgG1	Rat	F, C	100 µg	CL031B
	FITC	74	Mouse IgG1	Rat	F, C	100 µg	CL031F
	PE	74	Mouse IgG1	Rat	F, C	50 µg	CL031PE
C4	Purified	RmC16D2	Rat IgG2a	Mouse	IF, C, WB, E	250 µg	CL7504AP
	Biotin	RmC16D2	Rat IgG2a	Mouse	IF, E, WB, F, IHC, C	100 µg	CL7504B
	FITC	RmC16D2	Rat IgG2a	Mouse	IF	100 µg	CL7504F
C4b	Purified	Polyclonal	Chicken IgY	Human	E, WB, P, F	500 µg	CL2154AP
C5a	Purified	Polyclonal	Rabbit IgG	Human	E	200 µg	CL7635AP
	Purified	Polyclonal	Rabbit IgG	Human	E	100 µg	CL7635B
C5a/C5a(desArg) (Neo-Epitope)	Purified	C17/5	Mouse IgG1 K	Human	E, WB	200 µg	CL7624AP
	Biotin	C17/5	Mouse IgG1 K	Human	E, WB	100 µg	CL7624B
	FITC	C17/5	Mouse IgG1 K	Human	WB	100 µg	CL7624F
	PE	C17/5	Mouse IgG1 K	Human	WB	50 µg	CL7624PE
C5a Receptor (CD88)	Purified	20/70	Rat IgG2b	Mouse	F, IF, Blocking	250 µg	CL7588AP
	Biotin	20/70	Rat IgG2b	Mouse	F, IF, Blocking	100 µg	CL7588B
	FITC	20/70	Rat IgG2b	Mouse	F, IF, Blocking	100 µg	CL7588F
	PE	20/70	Rat IgG2b	Mouse	F, IF, Blocking	50 µg	CL7588PE
	Purified	8D6	Rat IgG2a	Human	F	250 µg	CL7688AP
	Biotin	8D6	Rat IgG2a	Human	F	100 µg	CL7688B
	FITC	8D6	Rat IgG2a	Human	F	100 µg	CL7688F
	PE	8D6	Rat IgG2a	Human	F	50 µg	CL7688PE
CD11b (Mac-1; Ly 40; CR3a)	Purified	M1/70.15	Rat IgG2b	Mouse	F, C, P, IP, WB, FN	250 µg	CL8941AP
	Biotin	M1/70.15	Rat IgG2b	Mouse	F, C, P	100 µg	CL8941B
	FITC	M1/70.15	Rat IgG2b	Mouse	F	100 µg	CL8941F
	PE	M1/70.15	Rat IgG2b	Mouse	F	50 µg	CL8941PE
CD21	Purified	21A/5	Mouse IgG1	Human	F, C	200 µg	CL7613AP
	Biotin	21A/5	Mouse IgG1	Human	F, C	100 µg	CL7613B
	FITC	21A/5	Mouse IgG1	Human	F, C	100 µg	CL7613F
	PE	21A/5	Mouse IgG1	Human	F, C	50 µg	CL7613PE
	APC	21A/5	Mouse IgG1	Human	F, C	100 µg	CL7613APC
CD35	Purified	To5	Mouse IgG1	Human	F, WB, C	200 µg	CL7614AP
	Biotin	To5	Mouse IgG1	Human	F, WB, C	100 µg	CL7614B
	FITC	To5	Mouse IgG1	Human	F, WB, C	100 µg	CL7614F
	PE	To5	Mouse IgG1	Human	F, WB, C	50 µg	CL7614PE
	APC	To5	Mouse IgG1	Human	F, C	100 µg	CL7614APC
Factor H	Purified	OX-24	Mouse IgG1	Human	E	250 µg	CL7672AP
	Biotin	OX-24	Mouse IgG1	Human	E	100 µg	CL7672B
	FITC	OX-24	Mouse IgG1	Human	E	100 µg	CL7672F
Factor I	Purified	OX-21	Mouse IgG1	Human	E	250 µg	CL7671AP
	Biotin	OX-21	Mouse IgG1	Human	E	100 µg	CL7671B

Legend for Applications:

B-AP= Blocking alternative pathway
FN= Functional Assay
F= Flow Cytometry

B-CP= Blocking classical pathway
IF= Immunofluorescence
P= Paraffin-Embedded Section

C= Cryostat Sections
IP= Immunoprecipitation

E= ELISA
WB= Western Blotting

NEED A SPECIFIC FORMAT OR BULK SIZE?
CONTACT US TO EXPLORE YOUR OPTIONS!
WWW.CEDARLANELABS.COM

Selected References for Complement C3 Antibodies

RmC11H9:

Jash A, et al. (2024) **Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice.** J Clin Invest. 134(8):e167665.

Quach TD, et al. (2022) **Context-dependent induction of autoimmunity by TNF signaling deficiency.** JCI Insight. 7(5):e149094.

Kuriakose J, et al. (2019) **Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis.** J Clin Invest. 129(6):2251-2265.

6C9:

Li Y, et al. (2024) **Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins.** Nat Nanotechnol. 19(2):246-254.

Dufloo J, et al. (2020) **Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.** EMBO Rep. 21(2):e49351.

10C7:

Lerch M, et al. (2022) **More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies.** Neurol Neuroimmunol Neuroinflamm. 10(1):e200059.

Sezin T, et al. (2019) **Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.** JCI Insight. 4(15):e128239.

Xu J, et al. (2018) **Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.** J Immunol. 200(12):4094-4101.

7C12:

DeLeo FR, et al. (2023) **Interaction of multidrug-resistant hypervirulent Klebsiella pneumoniae with components of human innate host defense.** mBio. 14(5):e0194923.

Moore SR, et al. (2023) **A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution.** Front Immunol. 13:918856.

Seguin-Devaux C, et al. (2019) **FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.** Mol Oncol. 13(12):2531-2553.

1H8:

Pumpuang A, et al. (2022) **Functional Activities of O-Polysaccharide and Hemolysin Coregulated Protein 1 Specific Antibodies Isolated from Melioidosis Patients.** Infect Immun. 90(11):e0021422.

Skarzynski M, et al. (2016) **Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.** Clin Cancer Res. 22(1):86-95.

Irvine KM, et al. (2016) **CR1g-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.** JCI Insight. 1(8):e86914.

Cumpelik A, et al. (2015) **Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG).** Am J Transplant. 15(10):2588-601.

CEDARLANE ADVANTAGE



**WORRY FREE
ORDERING**



**LOW, FLAT-RATE
SHIPPING**



**BEST VALUE
GUARANTEED**



**HUGE SELECTION
AND VARIETY**



**SALES AND
TECHNICAL SUPPORT**

CEDARLANE[®] 
Part of TCP Analytical Group

📍 CANADA

4410 Paletta Ct Suite A - L7L 5R2
Burlington, Ontario, Canada
E-mail: general@cedarlanelabs.com
Toll Free: 1-800-268-5058
Ph: (289) 288-0001
Fax: (289) 288-0020

📍 USA

1210 Turrentine St, Burlington, North
Carolina - 27215, United States
E-mail: service@cedarlanelabs.com
Toll Free: 1-800-721-1644
Ph: (336) 513-5135
Fax: (336) 513-5138